结直肠癌肝转移的区域治疗:选择何种方式及何时使用?
对于不可切除的结直肠癌肝转移(uCRLM),区域治疗利用肝脏双重血供实现选择性递送。肝动脉灌注泵(HAIP)化疗在切除后辅助治疗中可能有生存获益,与当代全身治疗联用安全且客观缓解率和转化切除率高;伊立替康药物洗脱微球经动脉化疗栓塞肝内客观缓解率高且安全性明确;经动脉放射性栓塞肝内缓解率高但一线或二线治疗未改善总生存或生活质量。最佳方案应与患者价值观和偏好一致。
要点
- HAIP化疗在CRLM切除后辅助治疗中可能有生存获益,与当代全身治疗联用安全且客观缓解率和转化切除率高。
- 伊立替康药物洗脱微球经动脉化疗栓塞肝内客观缓解率高,安全性明确。
- 经动脉放射性栓塞肝内缓解率高,但一线或二线治疗未改善总生存或生活质量。
核心结论
- 对于不可切除的结直肠癌肝转移,区域治疗可利用肝脏双重血供选择性递送治疗并限制全身副作用。
- 最佳治疗方式应与患者价值观、偏好和照护理念最一致。
研究设计与样本
- 综述,讨论结直肠癌肝转移区域治疗的整合,指出缺乏随机对照试验证据。
主要发现
- HAIP化疗在CRLM切除后辅助治疗中可能有生存获益。
- HAIP化疗可与当代全身治疗安全联用,在uCRLM患者中客观缓解率高且转化切除率高。
- 伊立替康药物洗脱微球经动脉化疗栓塞在uCRLM患者中肝内客观缓解率高且安全性明确。
- 经动脉放射性栓塞在uCRLM一线或二线治疗中肝内缓解率高,但未改善总生存或生活质量。
临床怎么用
- 一线治疗中,HAIP可考虑用于希望实现转化切除的积极患者。
- 化疗进展后,对于追求优化缓解率和区域控制的肝局限或肝为主CRLM患者,HAIP、经动脉化疗栓塞和经动脉放射性栓塞是可考虑的有价值治疗选择。
局限性
- 原文指出缺乏随机对照试验证据来指导区域治疗优化整合到CRLM管理中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For patients with unresectable colorectal liver metastases (uCRLM), regional therapies leverage the unique, dual blood supply to the liver; the hepatic artery is the main blood supply for liver tumors, whereas the portal vein supplies most normal hepatic parenchyma. Infusion of cancer therapies via the hepatic artery allows selective delivery to the tumors with relative sparing of normal liver tissue and little extrahepatic exposure, thus limiting systemic side effects. There is a paucity of randomized controlled trial evidence to inform the optimal integration of regional therapies into the management of CRLM. Hepatic arterial infusion pump (HAIP) chemotherapy has a potential survival benefit when used in the adjuvant setting after resection of CRLM. HAIP chemotherapy can be safely given with contemporary systemic therapies and is associated with a high objective response and rate of conversion to resectability in patients with uCRLM. Drug-eluting beads coated with irinotecan transarterial chemoembolization is associated with high objective response rates within the liver and has a well-established safety profile in patients with uCRLM. Transarterial radioembolization achieves high rates of response within the liver but is not associated with improvements in overall survival or quality of life in the first- or second-line setting for uCRLM. The best treatment approach is the one that most aligns with a given patients' values, preferences, and philosophy of care. In the first-line setting, HAIP could be offered to motivated patients who hope to achieve conversion to resectability. After progression on chemotherapy, HAIP, transarterial chemoembolization, and transarterial radioembolization are valuable treatment options to consider for patients with liver-limited or liver-predominant CRLM who seek to optimize response rates and regional control.
引用
- Raphael MJ, Karanicolas PJ. Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When? J Clin Oncol. 2022. PMID: 35649228. doi:10.1200/JCO.21.02505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。